These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

840 related articles for article (PubMed ID: 25374186)

  • 1. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
    Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
    Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
    Shah MA; Janjigian YY; Stoller R; Shibata S; Kemeny M; Krishnamurthi S; Su YB; Ocean A; Capanu M; Mehrotra B; Ritch P; Henderson C; Kelsen DP
    J Clin Oncol; 2015 Nov; 33(33):3874-9. PubMed ID: 26438119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I and pharmacokinetic study of capecitabine in combination with epirubicin and cisplatin in patients with inoperable oesophago-gastric adenocarcinoma.
    Evans TR; Pentheroudakis G; Paul J; McInnes A; Blackie R; Raby N; Morrison R; Fullarton GM; Soukop M; McDonald AC
    Ann Oncol; 2002 Sep; 13(9):1469-78. PubMed ID: 12196374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Feasibility study of docetaxel, oxaliplatin and capecitabine combination regimen in advanced gastric or gastroesophageal adenocarcinoma.
    Goel G; Jauhri M; Negi A; Aggarwal S
    Hematol Oncol Stem Cell Ther; 2010; 3(2):55-9. PubMed ID: 20543537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
    Inal A; Kaplan MA; Kucukoner M; Isikdogan A
    Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of 3-weekly docetaxel, capecitabine and oxaliplatin combination chemotherapy in patients with previously untreated advanced gastric cancer.
    Sym SJ; Ryu MH; Kang HJ; Lee SS; Chang HM; Lee JL; Kim TW; Yook JH; Oh ST; Kim BS; Kang YK
    Cancer Chemother Pharmacol; 2010 Jul; 66(2):373-80. PubMed ID: 19936751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
    Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
    Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modified docetaxel-cisplatin in combination with capecitabine as first-line treatment in metastatic gastric cancer. a phase II study.
    Polyzos A; Felekouras E; Karatzas T; Griniatsos J; Dimitroulis D; Polyzos K; Kontzoglou K; Mantas D; Karavokyros J; Nikiteas N; Tsavaris N; Syrigos K; Vafiadis I
    Anticancer Res; 2012 Sep; 32(9):4151-6. PubMed ID: 22993377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of weekly docetaxel, cisplatin, and 5-fluorouracil for locally advanced or metastatic gastric cancer patients with ECOG performance scores of 1 and 2.
    Turkeli M; Aldemir MN; Cayir K; Simsek M; Bilici M; Tekin SB; Yildirim N; Bilen N; Makas I
    Asian Pac J Cancer Prev; 2015; 16(3):985-9. PubMed ID: 25735393
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma.
    Ozdemir NY; Abali H; Oksüzoğlu B; Budakoglu B; Uncu D; Güler T; Odabaşi H; Zengin N
    Med Oncol; 2010 Sep; 27(3):680-4. PubMed ID: 19633962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study.
    Van Cutsem E; Boni C; Tabernero J; Massuti B; Middleton G; Dane F; Reichardt P; Pimentel FL; Cohn A; Follana P; Clemens M; Zaniboni A; Moiseyenko V; Harrison M; Richards DA; Prenen H; Pernot S; Ecstein-Fraisse E; Hitier S; Rougier P
    Ann Oncol; 2015 Jan; 26(1):149-156. PubMed ID: 25416687
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer.
    Kim TW; Kang YK; Ahn JH; Chang HM; Yook JH; Oh ST; Kim BS; Lee JS
    Ann Oncol; 2002 Dec; 13(12):1893-8. PubMed ID: 12453857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma.
    Bayraktar UD; Bayraktar S; Hosein P; Chen E; Koniaris LG; Rocha-Lima CM; Montero AJ
    Med Oncol; 2012 Sep; 29(3):1707-10. PubMed ID: 22033912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel and capecitabine for advanced gastric cancer: investigating dose-dependent efficacy in two patient cohorts.
    Thuss-Patience PC; Kretzschmar A; Dogan Y; Rothmann F; Blau I; Schwaner I; Breithaupt K; Bichev D; Grothoff M; Grieser C; Reichardt P
    Br J Cancer; 2011 Aug; 105(4):505-12. PubMed ID: 21792201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of weekly docetaxel in combination with capecitabine in advanced gastric and gastroesophageal adenocarcinomas.
    Lo SS; Khorana AA; Javle M; Simon S; Kiefer G; Rajasenan K; Wang H; Hantel A; Shayne M; Hwang J; Schmotzer A; Ramanathan RK
    Oncology; 2010; 78(2):125-9. PubMed ID: 20389134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma.
    Shah MA; Jhawer M; Ilson DH; Lefkowitz RA; Robinson E; Capanu M; Kelsen DP
    J Clin Oncol; 2011 Mar; 29(7):868-74. PubMed ID: 21189380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.
    Wang J; Xu R; Li J; Bai Y; Liu T; Jiao S; Dai G; Xu J; Liu Y; Fan N; Shu Y; Ba Y; Ma D; Qin S; Zheng L; Chen W; Shen L
    Gastric Cancer; 2016 Jan; 19(1):234-44. PubMed ID: 25604851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study.
    Orditura M; Martinelli E; Galizia G; Carlomagno C; Aurilio G; Vecchione L; Lieto E; De Placido S; Catalano G; Ciardiello F; De Vita F
    Ann Oncol; 2006 Oct; 17(10):1529-32. PubMed ID: 16873436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
    Zhang J; Xiao Y; Lu M; Li J; Zhang XD; Li Y; Shen L
    Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):312-5. PubMed ID: 19615292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.